New hope for kids with relapsed neuroblastoma: BEACON2 trial tests drug cocktails

NCT ID NCT07334301

Recruiting now Disease control Sponsor: University of Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial is testing several combinations of existing drugs (dinutuximab beta, bevacizumab, irinotecan, and temozolomide) in children whose neuroblastoma has come back or not responded to standard treatment. About 160 participants will be randomly assigned to different treatment arms to see which combination works best and is safe. The goal is to improve survival and learn more about the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dinutuximab beta, bevacizumab, irinotecan, temozolomide
What this could lead to: If successful, this trial could identify better treatment combinations that improve survival for children with relapsed neuroblastoma.
What could go wrong: This is an early-phase trial (phase 1/2) with a small number of participants, so results may not apply to all patients. The drugs can cause side effects like infection or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED NEUROBLASTOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Addenbrookes Hospital
RECRUITING

Cambridge, United Kingdom

Contact
Alder Hey Hospital
RECRUITING

Liverpool, United Kingdom

Contact
Birmingham Children's Hospital
RECRUITING

Birmingham, United Kingdom

Contact
Bristol Royal Hospital for Children
RECRUITING

Bristol, United Kingdom

Contact
Children's Hospital for Wales
RECRUITING

Cardiff, United Kingdom

Contact
Cliniques Universitaires Saint-Luc (CUSL)
NOT_YET_RECRUITING

Brussels, Belgium
Great Ormond Street Hospital
RECRUITING

London, United Kingdom

Contact
John Radcliffe Hospital
NOT_YET_RECRUITING

Oxford, United Kingdom

Contact
Leeds General Infirmary
RECRUITING

Leeds, United Kingdom

Contact
Nottingham Children's Hospital
NOT_YET_RECRUITING

Nottingham, United Kingdom

Contact
Royal Aberdeen Children's Hospital
RECRUITING

Aberdeen, United Kingdom

Contact
Royal Belfast Hospital for Sick Children
NOT_YET_RECRUITING

Belfast, United Kingdom

Contact
Royal Hospital for Children
NOT_YET_RECRUITING

Glasgow, United Kingdom

Contact
Royal Hospital for Sick Children
NOT_YET_RECRUITING

Edinburgh, United Kingdom

Contact
Royal Manchester Children's Hospital
RECRUITING

Manchester, United Kingdom

Contact
Royal Marsden Hospital
RECRUITING

Sutton, United Kingdom

Contact
Royal Victoria Infirmary
RECRUITING

Newcastle upon Tyne, United Kingdom

Contact
Sheffield Children's Hospital
RECRUITING

Sheffield, United Kingdom

Contact
Southampton General Hospital
RECRUITING

Southampton, United Kingdom

Contact Email: •••••@•••••
St. Anna Children´s Hospital
NOT_YET_RECRUITING

Vienna, Austria
Starship Children's Hospital (SSH)
NOT_YET_RECRUITING

Auckland, New Zealand
Sydney Children's Hospital (SCH)
NOT_YET_RECRUITING

Sydney, Australia
University College London Hospital
NOT_YET_RECRUITING

London, United Kingdom

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.